Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT03199053
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT03199053 -
2015-005042-66
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Finland, India, Israel, Italy, Malaysia, Mexico, New Zealand, Philippines, Poland, Russia, South Korea, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03199053. Randomized; double masking; primary purpose treatment. Start 2017-10-11 (actual); primary completion 2023-02-01 (actual). Results posted on 2024-04-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03199053- Content hash
6838533f144dfd6da04b4efd7290f8b3355518a71aace30c5821d114f548c5ad